re: FDA Expected to Authorize Pfizer and Merck Covid Pills This Week

Pfizer and Merck will get authorization but Romark's NT-300 pill that completed phase 3 clinical trials in April 2021 and reduced progression to severe Covid-19 disease by 85% and has been working to get EUA but has not been able to.

Romark announces initial results of phase 3 clinical trial of NT-300 for the treatment of covid-19

Nitazoxanide is a broad-spectrum thiazolide antiparasitic agent that is approved by the Food and Drug Administration (FDA) for the treatment of Cryptosporidium parvum and Giardia duodenalis infections in children aged =1 year and adults. Nitazoxanide is rapidly metabolized to its active metabolite, tizoxanide, and has in vitro antiviral activity against a range of viruses, including influenza viruses, hepatitis B and C viruses, norovirus, rotavirus, Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2.1-3

NIH Covid-19 Treatment Guidelines - Nitaxoxanide